Many of these downstream pathways – particularly the JAK–STAT pathway, are also targeted by several newly described leukemogenic fusion proteins that induce a disease similar to Ph+ ALL, but without a BCR–ABL1 rearrangement. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.